Pain management in IBD

Inflammatory Bowel Disease Monitor

Volumn 10, Issue 1, 2009, Pages 1-10

  Grover, Madhusudan ^a   Drossman, Douglas A ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952578325     PISSN: 14667401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975;68:627-35.
2. Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis 2009;15:778-88.
3. Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol 2009;7:48-53.
4. Drossman DA. Functional versus organic: an inappropriate dichotomy for clinical care. Am J Gastroenterol 2006;101:1172-5. (Pubitemid 43829976)
5. Farrokhyar F, Marshall JK, Easterbrook B et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006;12:38-46. (Pubitemid 43032450)
6. Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-5.
7. Bayless TM, Harris ML. Inflammatory bowel disease and irritable bowel syndrome. Med Clin North Am 1990;74:21-8.
8. Simren M, Axelsson J, Gillberg R et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002;97:389-96. (Pubitemid 34160766)
9. Minderhoud IM, Oldenburg B, Wismeijer JA et al. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004;49:469-74. (Pubitemid 38453568)
10. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - a metaanalysis. Am J Gastroenterol 2006;101:1894-9.
11. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702. (Pubitemid 38298317)
12. Drossman DA. Mind over matter in the postinfective irritable bowel. Gut 1999;44:306-7. (Pubitemid 29119319)
13. Shen B, Achkar JP, Lashner BA et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol 2002;97:972-7. (Pubitemid 34408256)
14. Snape WJ Jr, Williams R, Hyman PE. Defect in colonic smooth muscle contraction in patients with ulcerative colitis. Am J Physiol 1991;261:G987-91.
15. Garrett JM, Sauer WG, Moertel CG. Colonic motility in ulcerative colitis after opiate administration. Gastroenterology 1967;53:93-100.
16. Annese V, Bassotti G, Napolitano G et al. Gastrointestinal motility disorders in patients with inactive Crohn's disease. Scand J Gastroenterol 1997;32:1107-17. (Pubitemid 27523842)
17. Vermillion DL, Huizinga JD, Riddell RH et al. Altered small intestinal smooth muscle function in Crohn's disease. Gastroenterology 1993;104:1692-9. (Pubitemid 23235460)
18. Casey KL. Match and mismatch: identifying the neuronal determinants of pain. Ann Intern Med 1996;124:995-8.
19. Drossman DA. Functional abdominal pain syndrome. Clin Gastroenterol Hepatol 2004;2:353-65. (Pubitemid 38561231)
20. Rainville P, Duncan GH, Price DD et al. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 1997;277:968-71. (Pubitemid 27366684)
21. Drossman DA, Camilleri M, Mayer EA et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31. (Pubitemid 35408332)
22. Coderre TJ, Katz J, Vaccarino AL et al. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993;52:259-85. (Pubitemid 23080546)
23. Sperber AD, Morris CB, Greemberg L et al. Development of abdominal pain and IBS following gynecological surgery: a prospective, controlled study. Gastroenterology 2008;134:75-84. (Pubitemid 350309329)
24. Longstreth GF, Preskill DB, Youkeles L. Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome. Dig Dis Sci 1990;35:1285-90. (Pubitemid 20377952)
25. Jess P, Jess T, Beck H et al. Neuroticism in relation to recovery and persisting pain after laparoscopic cholecystectomy. Scand J Gastroenterol 1998;33:550-3. (Pubitemid 28277258)
26. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136:1979-88.
27. Minderhoud IM, Smout AJ, Oldenburg B et al. A pilot study on chemospecific duodenal visceral sensitivity in inflammatory bowel disease in remission. Digestion 2006;73:151-9. (Pubitemid 44155917)
28. Minderhoud IM, Oldenburg B, Schipper ME et al. Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission. Clin Gastroenterol Hepatol 2007;5:714-20. (Pubitemid 46830050)
29. Melzack R, Wall P. Gate-control and other mechanisms. In: Melzack R, Wall P, editors. The challenge of pain. 2nd edition. London: Pelican Books, 1988:165-93.
30. Drossman DA, Whitehead WE, Toner BB et al. What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol 2000;95:974-80. (Pubitemid 30196734)
31. Mertz HR. Altered CNS processing of visceral pain in IBS. In: Camilleri M, Spiller RC, editors. Irritable bowel syndrome: diagnosis and treatment. 1st edition. London: WB Saunders, 2002:55-68.
32. Mertz H, Morgan V, Tanner G et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000;118:842-8. (Pubitemid 30243747)
33. Naliboff BD, Derbyshire SW, Munakata J et al. Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med 2001;63:365-75. (Pubitemid 32467111)
34. Drossman DA, Ringel Y, Vogt BA et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 2003;124:754-61. (Pubitemid 36268492)
35. Morgan V, Pickens D, Gautam S et al. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005;54:601-7. (Pubitemid 40559240)
36. Mayberg HS, Brannan SK, Mahurin RK et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997;8:1057-61. (Pubitemid 27152174)
37. Drossman DA, Ringel Y. Psychosocial factors in ulcerative colitis and Crohn's disease. In: Sartor RB, Sandborn W, editors. Kirsner's inflammatory bowel disease. 6th edition. London: Harcourt Publishers Limited, 2004:340-56.
38. Drossman DA, Leserman J, Mitchell CM et al. Health status and health care use in persons with inflammatory bowel disease. A national sample. Dig Dis Sci 1991;36:1746-55.
39. Drossman DA. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom Med 1998;60:258-67. (Pubitemid 28279969)
40. Levenstein S, Prantera C, Varvo V et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000;95:1213-20. (Pubitemid 30263515)
41. Mittermaier C, Dejaco C, Waldhoer T et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004;66:79-84. (Pubitemid 38146536)
42. Mardini HE, Kip KE, Wilson JW. Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci 2004;49:492-7. (Pubitemid 38455480)
43. Mawdsley JE, Macey MG, Feakins RM et al. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology 2006;131:410-9. (Pubitemid 44142453)
44. Kurina LM, Goldacre MJ, Yeates D et al. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health 2001;55:716-20. (Pubitemid 32881818)
45. Schwarz SP, Blanchard EB. Evaluation of a psychological treatment for inflammatory bowel disease. Behav Res Ther 1991;29:167-77.
46. Pace F, Molteni P, Bollani S et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol 2003;38:1031-8. (Pubitemid 37352465)
47. Talal AH, Drossman DA. Psychosocial factors in inflammatory bowel disease. Gastroenterol Clin North Am 1995;24:699-716.
48. Walker EA, Gelfand MD, Gelfand AN et al. The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease. Gen Hosp Psychiatry 1996;18:220-9. (Pubitemid 26251507)
49. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol 2005;100:2225-9.
50. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
51. Grunkemeier DM, Cassara JE, Dalton CB et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007;5:1126-39. (Pubitemid 47488969)
52. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci 2001;24:450-5. (Pubitemid 32695356)
53. Edwards JT, Radford-Smith GL, Florin TH. Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics. J Gastroenterol Hepatol 2001;16:1235-8. (Pubitemid 34088270)
54. Hanson KA, Loftus EV Jr, Harmsen WS et al. Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study. Inflamm Bowel Dis 2009;15:772-7.
55. Levinson W, Roter DL, Mullooly JP et al. Physician-patient communication. The relationship with malpractice claims among primary care physicians and surgeons. JAMA 1997;277:553-9. (Pubitemid 27083985)
56. Mikocka-Walus AA, Turnbull DA, Moulding NT et al. "It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease. BMC Gastroenterol 2007;7:38.
57. Perera TD, Park S, Nemirovskaya Y. Cognitive role of neurogenesis in depression and antidepressant treatment. Neuroscientist 2008;14:326-38. (Pubitemid 352010067)
58. Bremner JD. Does stress damage the brain? Biol Psychiatry 1999;45:797-805.
59. Valet M, Gundel H, Sprenger T et al. Patients with pain disorder show gray-matter loss in pain-processing structures: a voxel-based morphometric study. Psychosom Med 2009;71:49-56.
60. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008;11:1169-80.
61. Geddes JR, Carney SM, Davies C et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-61. (Pubitemid 36246547)
62. Grover M, Drossman DA. Psychotropic agents in functional gastrointestinal disorders. Curr Opin Pharmacol 2008;8:715-23.
63. Halpert A, Dalton CB, Diamant NE et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005;100:664-71. (Pubitemid 40487567)
64. Thiwan S, Drossman DA, Morris CB et al. Not all side effects associated with tricyclic antidepressant therapy are true side effects. Clin Gastroenterol Hepatol 2009;7:446-51.
65. Grover M, Drossman DA. Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders. Gastrointest Endosc Clin N Am 2009;19:151-70, vii-viii.
66. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008;8:690-6.
67. Grover M, Dorn SD, Weinland SR et al. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci 2009;54:1284-91.
68. Emami MH, Gholamrezaei A, Daneshgar H. Hypnotherapy as an adjuvant for the management of inflammatory bowel disease: a case report. Am J Clin Hypn 2009;51:255-62.
69. Miller V, Whorwell PJ. Treatment of inflammatory bowel disease: a role for hypnotherapy? Int J Clin Exp Hypn 2008;56:306-17. (Pubitemid 351892496)
70. Keefer L, Keshavarzian A. Feasibility and acceptability of gut-directed hypnosis on inflammatory bowel disease: a brief communication. Int J Clin Exp Hypn 2007;55:457-66. (Pubitemid 47357182)
71. Mussell M, Bocker U, Nagel N et al. Reducing psychological distress in patients with inflammatory bowel disease by cognitive-behavioural treatment: exploratory study of effectiveness. Scand J Gastroenterol 2003;38:755-62. (Pubitemid 36920498)
72. von Wietersheim J, Kessler H. Psychotherapy with chronic inflammatory bowel disease patients: a review. Inflamm Bowel Dis 2006;12:1175-84. (Pubitemid 44847475)
73. Gruzelier JH. A review of the impact of hypnosis, relaxation, guided imagery and individual differences on aspects of immunity and health. Stress 2002;5:147-63. (Pubitemid 34532752)
74. Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104 (Suppl 1):S1-35.
75. Creed F, Fernandes L, Guthrie E et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-17. (Pubitemid 36169247)